Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Analytica Chimica Acta

• Publication date

  2012-01-13

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.aca.2011.10.026PMID 22123108
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• National Center for Biotechnology Information (NCBI)

  2012cited by this paper
• Ultra-performance liquid chromatography coupled to mass spectrometry as a sensitive and powerful technology for metabolomic studies.

  2011cited by this paper
• Novel strategies for microdose studies using non-radiolabeled compounds.

  2011cited by this paper
• Determination of L-dopa, carbidopa, 3-O-methyldopa and entacapone in human plasma by HPLC-ED.

  2011cited by this paper
• Nitecapone reduces development and symptoms of neuropathic pain after spinal nerve ligation in rats 1

  2011cited by this paper
• Ultra high pressure liquid chromatography for crude plant extract profiling.

  2011cited by this paper
• Development of characterization methods for entacapone in a pharmaceutical bulk.

  2011cited by this paper
• Discovery of a long-acting, peripherally selective inhibitor of catechol-O-methyltransferase.

  2010cited by this paper
• A Double‐Blind, Randomized, Placebo and Active‐Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease

  2010cited by this paper
• The chemistry of catechol-O-methyltransferase inhibitors.

  2010cited by this paper
• Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans.

  2010cited by this paper
• Ultraperformance liquid chromatography with electrospray ionization ion trap mass spectrometry for chondroitin disaccharide analysis.

  2010cited by this paper
• New trends in fast and high-resolution liquid chromatography: a critical comparison of existing approaches

  2010cited by this paper
• LC determination of entacapone in tablets: in vitro dissolution studies.

  2010cited by this paper
• Identification of metabolite profiles of the catechol-O-methyl transferase inhibitor tolcapone in rat urine using LC/MS-based metabonomics analysis.

  2009cited by this paper
• A review of current trends and advances in modern bio-analytical methods: chromatography and sample preparation.

  2009cited by this paper
• Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily

  2009cited by this paper
• A global view of Parkinson's disease pathogenesis: implications for natural history and neuroprotection.

  2009cited by this paper
• Chromatographic separation of (E)- and (Z)-isomers of entacapone and their simultaneous quantitation in human plasma by LC-ESI-MS/MS.

  2009cited by this paper
• Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone.

  2009cited by this paper
• Development and application of a high-performance liquid chromatographic method for the determination of in vitro drug release of levodopa, carbidopa, and entacapone from a tablet formulation.

  2009cited by this paper
• Epidemiology of Parkinson’s disease

  2008cited by this paper
• Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment.

  2008cited by this paper
• Levodopa: Past, Present, and Future

  2008cited by this paper
• Evidence‐Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease

  2008cited by this paper
• Optimising levodopa therapy

  2008cited by this paper
• The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease.

  2007cited by this paper
• Catechol-O-methyltransferase and its inhibitors in Parkinson's disease.

  2007cited by this paper
• Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples

  2007cited by this paper
• Stability-Indication LC Determination of Entacapone in Tablets

  2007cited by this paper
• Human Metabolism of Nebicapone (BIA 3-202), a Novel Catechol-O-Methyltransferase Inhibitor: Characterization of in Vitro Glucuronidation

  2006cited by this paper
• The Lipophilicity Behavior of Three Catechol-O-methyltransferase (COMT) Inhibitors and Simple Analogues

  2006cited by this paper
• Rapid simultaneous determination of metabolic clearance of multiple compounds catalyzed in vitro by recombinant human UDP-glucuronosyltransferases.

  2005cited by this paper
• The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.

  2005cited by this paper
• RP-HPLC analysis of phenolic compounds and flavonoids in beverages and plant extracts using a CoulArray detector.

  2005cited by this paper
• Tolcapone

  2005cited by this paper
• The combination of liquid chromatography/tandem mass spectrometry and chip-based infusion for improved screening and characterization of drug metabolites.

  2005cited by this paper
• High-performance liquid chromatography method for the quantification of entacapone in human plasma.

  2005cited by this paper
• Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone

  2004cited by this paper
• ASSESSMENT OF CATECHOL INDUCTION AND GLUCURONIDATION IN RAT LIVER MICROSOMES

  2004cited by this paper
• Pharmacokinetics and Pharmacodynamics of BIA 3-202, a Novel COMT Inhibitor, during First Administration to Humans

  2003cited by this paper
• In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.

  2003cited by this paper
• Pharmacokinetics and Pharmacodynamics of Entacapone and Tolcapone after Acute and Repeated Administration: A Comparative Study in the Rat

  2003cited by this paper
• Characterization of catechol glucuronidation in rat liver.

  2002cited by this paper
• Catechol-O-methyltransferase and Parkinson's disease.

  2002cited by this paper
• Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man

  2001cited by this paper
• Quantitation of entacapone glucuronide in rat plasma by on-line coupled restricted access media column and liquid chromatography-tandem mass spectrometry.

  2001cited by this paper
• Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson’s Disease

  2000cited by this paper
• Synthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacapone.

  2000cited by this paper
• The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases.

  2000cited by this paper
• Determination of the catechol-O-methyltransferase inhibitor tolcapone and three of its metabolites in animal and human plasma and urine by reversed-phase high-performance liquid chromatography with ultraviolet detection.

  1999cited by this paper
• The rise and fall of tolcapone

  1999cited by this paper
• Mass spectrometric and tandem mass spectrometric behavior of nitrocatechol glucuronides: A comparison of atmospheric pressure chemical ionization and electrospray ionization

  1999cited by this paper
• Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition

  1999cited by this paper
• Micellar electrokinetic capillary chromatography method for direct determination of glucuronides of entacapone and its (Z)-isomer in human urine.

  1999cited by this paper
• Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase.

  1999cited by this paper
• Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.

  1999cited by this paper
• Tolcapone and fulminant hepatitis.

  1998cited by this paper
• Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites *

  1998cited by this paper
• Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy

  1998cited by this paper
• Glucuronidation of Entacapone, Nitecapone, Tolcapone, and Some Other Nitrocatechols by Rat Liver Microsomes

  1997cited by this paper
• Integrated pharmacokinetics and pharmacodynamics of the novel catechol‐O‐methyltransferase inhibitor tolcapone during first administration to humans

  1995cited by this paper
• Identification of major metabolites of the catechol-O-methyltransferase inhibitor nitecapone in the rat and dog.

  1993cited by this paper
• Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans.

  1993cited by this paper
• Analyses of hazardous substances in biological materials

  1993cited by this paper
• Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection.

  1992cited by this paper
• Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine.

  1992cited by this paper
• Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone

  1991cited by this paper
• Determination of nitecapone and (13C6)nitecapone in human plasma by gas chromatography/mass spectrometry.

  1991cited by this paper
• Identification of major metabolites of the catechol-O-methyltransferase-inhibitor nitecapone in human urine.

  1991cited by this paper
• Determination of a catechol-O-methyltransferase inhibitor, nitecapone, in human plasma and urine by liquid chromatography.

  1991cited by this paper
• Exercise hemodynamics and catecholamine metabolism after catechol‐O‐methyltransferase inhibition with nitecapone

  1990cited by this paper
• open access to scientific and medical research Open Access Full Text Article EXPERT OPINION

  year unknowncited by this paper

• A Review on: Bioanayltical Method Development and Validation

  2025cites this paper
• Rescuing a Troubled Tolcapone with PEGylated PLGA Nanoparticles: Design, Characterization, and Hepatotoxicity Evaluation.

  2024cites this paper
• 3-Methoxytyrosine as an indicator of dopaminergic manipulation in equine plasma.

  2023cites this paper
• DESI-MSI-based technique to unravel spatial distribution of COMT inhibitor Tolcapone.

  2023cites this paper
• Liquid chromatographic methods in the determination of inosine monophosphate dehydrogenase enzyme activity: a review.

  2023cites this paper
• Metabolomics in clinical and forensic toxicology, sports anti‐doping and veterinary residues

  2022cites this paper
• In vitro and in vivo characterization of Entacapone-loaded nanostructured lipid carriers developed by quality-by-design approach

  2022cites this paper
• Developmental and behavioral toxicity assessment of opicapone in zebrafish embryos.

  2022cites this paper
• Method Development and Validation of Simultaneous Determination of Assay of Quinapril and Tolcapone

  2022cites this paper
• Intelligence benefit of the 3-methoxytyramine to tyramine ratio in equine urine.

  2022cites this paper
• Development and validation of a stability indicating related substances of Opicapone by reverse phase high performance liquid chromatography and its degradation

  2022cites this paper
• A simple and efficient method for simultaneous quantification of levodopa and carbidopa based on controlled oxidation process

  2021cites this paper
• Discovery and characterization of flavonoids in vine tea as catechol-O-methyltransferase inhibitors.

  2021cites this paper
• Entacapone/Tolcapone/Opicapone for Treating Parkinson’s Disease

  2020cites this paper
• Molecularly imprinted polymers (MIPs) based electrochemical sensors for the determination of catecholamine neurotransmitters – Review

  2020cites this paper
• Design, synthesis and evaluation of 3-hydroxypyridin-4-ones as inhibitors of catechol-O-methyltransferase

  2020cites this paper
• Targeting epidermal growth factor receptors inhibition in non-small-cell lung cancer: a computational approach

  2018cites this paper
• Pharmacophore-based virtual screening of catechol-o-methyltransferase (COMT) inhibitors to combat Alzheimer’s disease

  2018cites this paper
• Xenobiotic C-sulfonate derivatives; metabolites or metabonates?

  2018cites this paper
• Sensitive LC-MS/MS method for quantitation of levodopa and carbidopa in plasma: application to a pharmacokinetic study.

  2018cites this paper
• Metabolism and elimination of the catechol-o-methyltransferase inhibitor tolcapone in the horse.

  2018cites this paper
• A Screening Strategy for Evaluation of Drug Transport across the Blood-Brain Barrier: Application to Catechol-O-methyltransferase Inhibitors, Dopamine β-hydroxylase Inhibitors and Dibenz[b,f]azepine-5-carboxamide Derivatives

  2018cites this paper
• Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy

  2017cites this paper
• Quantitation of levodopa and carbidopa in rat plasma by LC-MS/MS: The key role of ion-pairing reversed-phase chromatography.

  2017cites this paper
• Elucidation of the Impact of P-glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Catechol-O-Methyltransferase Inhibitors

  2017cites this paper
• A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates.

  2016cites this paper
• Development of a liquid chromatography assay for the determination of opicapone and BIA 9-1079 in rat matrices.

  2016cites this paper
• Hydrophilic Interaction Liquid Chromatography/Mass Spectrometry: An Attractive and Prospective Method for the Quantitative Bioanalysis in Drug Metabolism.

  2016cites this paper
• Simultaneous determination of levodopa, carbidopa, entacapone, tolcapone, 3-O-methyldopa and dopamine in human plasma by an HPLC-MS/MS method.

  2015cites this paper
• Catechol-O-Methyltransferase Inhibitors in Parkinson’s Disease

  2015cites this paper
• INVESTIGATION OF HNO-INDUCED MODIFICATIONS IN VARIOUS SYSTEMS

  2014cites this paper
• A new HILIC-MS/MS method for the simultaneous analysis of carbidopa, levodopa, and its metabolites in human plasma.

  2014cites this paper
• PHARMACOLOGICAL THERAPY FOR MOTOR SYMPTOMS OF PARKINSON'S DESEASE: LEVODOPA

  2014cites this paper
• Bioanalytical Method Validation and Its Pharmaceutical Application- AReview

  2014cites this paper
• Determinação de levodopa, carbidopa, entacapona, tolcapona, 3-0-metildopa e dopamina em plasma humano utilizando CLAE-EM/EM

  2014cites this paper
• TLC of Antiparkinsonians

  2013cites this paper
• Use of catechol‐O‐methyltransferase inhibition to minimize L‐3,4‐dihydroxyphenylalanine‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned macaque

  2013cites this paper
• An HPLC-DAD method for the simultaneous quantification of opicapone (BIA 9-1067) and its active metabolite in human plasma.

  2013cites this paper
• Development and Validation of Stability-indicating Rp-hplc Assay Method for Entacapone in Entacapone Tablets

  2013cites this paper